Brazil Sao Paulo State Bhutantan Institute announced the final results of the 3rd phase clinical trials of the CoronaVac vaccine developed by Sinovac Biotech yesterday.
The protective effect of the vaccine against all COVID-19 cases, including mild cases that do not require medical intervention, was increased from 50,38 percent announced in January to 50,7 percent, while the protective effect of the vaccine against cases with obvious symptoms and requiring medical intervention was also increased. It was increased from 78 percent announced in January to 83,7 percent.
The study showed that if the interval between two doses of vaccine was relatively long, the protective effect of CoronaVac against all cases, including mild cases that did not require medical treatment, could increase to 62,3 percent. As a result of the research, it was determined that the optimal interval between two doses of vaccine was 28 days.
The research also shows that CoronaVac is effective against P.1 and P.2 mutant viruses seen in Brazil. The results of the aforementioned research initiated by the Bhutantan Institute were presented to the medical journal The Lancet for evaluation. The 3rd phase clinical trials of the CoronaVac vaccine, developed by Beijing Sinovac Biotech company, were held in Brazil on 21 July-16 December 2020.
Source: China International Radio